BACKGROUND Chronic kidney disease (CKD) is associated with elevated serum fibroblast growth factor 23 (FGF23) which correlates with increased cardiovascular risk. Prior data suggest serum FGF23 is also associated with increased adiposity. We tested the hypothesis that an intervention involving caloric restriction and aerobic exercise to reduce body weight would reduce serum FGF23 in patients with moderate to severe CKD. METHODS We performed a secondary analysis of data from a 2Χ2 factorial randomized trial enrolling 103 participants randomized to receive combined caloric restriction and aerobic exercise, caloric restriction alone, aerobic exercise alone, or usual care. Enrollees were persons with a median estimated glomerular filtration ra...
BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early...
Increased fibroblast growth factor 23 (FGF23), a bone-derived hormone involved in the regulation of ...
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates phosphate homeostasis. ...
BACKGROUND Chronic kidney disease (CKD) is associated with elevated serum fibroblast growth factor 2...
CKD is steadily increasing along with obesity worldwide. Furthermore, obesity is a proinflammatory r...
Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk...
BACKGROUND AND AIMS: Obesity is a pro-inflammatory risk factor for progression of CKD and cardiovasc...
CKD is steadily increasing along with obesity worldwide. Furthermore, obesity is a proinflammatory r...
BACKGROUND: Cardiovascular risk is increased in patients with chronic kidney disease (CKD). Fibrobla...
Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular morbidity ...
Chronic kidney disease (CKD) is a public health epidemic that affects millions of people worldwide. ...
The progressively increasing prevalence of the Metabolic Syndrome (MetS) has emerged as a major glob...
BACKGROUND: Fibroblast growth factor 23 (FGF23) has emerged as a risk factor for cardiovascular dise...
BACKGROUND : Chronic kidney disease (CKD) is a major public health problem all over the world lead...
Fibroblast growth factor-23 (FGF23) was initially identified as the causative factor of autosomal do...
BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early...
Increased fibroblast growth factor 23 (FGF23), a bone-derived hormone involved in the regulation of ...
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates phosphate homeostasis. ...
BACKGROUND Chronic kidney disease (CKD) is associated with elevated serum fibroblast growth factor 2...
CKD is steadily increasing along with obesity worldwide. Furthermore, obesity is a proinflammatory r...
Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk...
BACKGROUND AND AIMS: Obesity is a pro-inflammatory risk factor for progression of CKD and cardiovasc...
CKD is steadily increasing along with obesity worldwide. Furthermore, obesity is a proinflammatory r...
BACKGROUND: Cardiovascular risk is increased in patients with chronic kidney disease (CKD). Fibrobla...
Patients with chronic kidney disease (CKD) have a greatly enhanced risk of cardiovascular morbidity ...
Chronic kidney disease (CKD) is a public health epidemic that affects millions of people worldwide. ...
The progressively increasing prevalence of the Metabolic Syndrome (MetS) has emerged as a major glob...
BACKGROUND: Fibroblast growth factor 23 (FGF23) has emerged as a risk factor for cardiovascular dise...
BACKGROUND : Chronic kidney disease (CKD) is a major public health problem all over the world lead...
Fibroblast growth factor-23 (FGF23) was initially identified as the causative factor of autosomal do...
BACKGROUND: Fibroblast growth factor 23 (FGF23), a phosphate-regulating hormone that increases early...
Increased fibroblast growth factor 23 (FGF23), a bone-derived hormone involved in the regulation of ...
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates phosphate homeostasis. ...